Clinical Trials

Starpharma initiates U.S. NIH-funded trial of microbicide for sexually transmitted diseases

Published in AIDS Weekly, September 25th, 2006

Starpharma Holdings Limited (SPL) announced the commencement of a phase 1 safety trial in men for its lead product VivaGel (SPL7013 Gel) following successful review by the U.S. Food and Drug Administration (FDA), local ethics committees, and the U.S. National Institutes of Health (NIH).

VivaGel is currently in development as a microbicide for the prevention of the sexually transmitted infections, genital herpes and HIV/AIDS. It has already been successfully tested in a phase 1 safety study in women. The trial announced is being conducted to provide safety data for VivaGel in men who may be exposed to product used by their female partners.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2006-09-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry